Literature DB >> 21353743

Diagnostic, treatment, and prevention protocols for canine heartworm infection in animal sheltering agencies.

Kathleen N Colby1, Julie K Levy, Kiri F Dunn, Rachel I Michaud.   

Abstract

The high prevalence of heartworm infection in shelter dogs creates a dilemma for shelter managers, who frequently operate with insufficient funding, staffing, and expertise to comply with heartworm guidelines developed for owned pet dogs. The purpose of this study was to survey canine heartworm management protocols used by 504 animal sheltering agencies in the endemic states of Alabama, Florida, Georgia, and Mississippi. Open-admission shelters, which tended to be larger and more likely to perform animal control functions, were less likely (41%) to test all adult dogs than were limited-admission shelters (80%), which tended to be smaller non-profit humane agencies, and foster programs (98%) based out of private residences. Open-admission shelters were more likely to euthanize infected dogs (27%) or to release them without treatment (39%), whereas limited-admission shelters and foster programs were more likely to provide adulticide therapy (82% and 89%, respectively). Of the 319 agencies that treated infections, 44% primarily used a standard two-dose melarsomine protocol, and 35% primarily used a three-dose split-treatment melarsomine protocol. Long-term low-dose ivermectin was the most common treatment used in 22% of agencies. Open-admission shelters were less likely (35%) to provide preventive medications for all dogs than were limited-admission shelters (82%) and foster programs (97%). More agencies used preventives labeled for monthly use in dogs (60%) than ivermectin products labeled for livestock (38%). The most common reason diagnostic testing and preventive medication was not provided was cost. These results indicate a lack of protocol uniformity among agencies and insufficient resources to identify, treat, and prevent infection. Sheltering agencies and companion animal health industries should develop guidelines that are feasible for use in sheltering agencies and provide improved access to preventive and treatment strategies for management of Dirofilaria immitis.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21353743     DOI: 10.1016/j.vetpar.2011.01.018

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  6 in total

1.  Parasite control in Canadian companion animal shelters and a cost-comparison of anthelmintics.

Authors:  Janna M Schurer; Christina McKenzie; Patricia M Dowling; Emilie Bouchard; Emily J Jenkins
Journal:  Can Vet J       Date:  2015-09       Impact factor: 1.008

2.  Forecasting United States heartworm Dirofilaria immitis prevalence in dogs.

Authors:  Dwight D Bowman; Yan Liu; Christopher S McMahan; Shila K Nordone; Michael J Yabsley; Robert B Lund
Journal:  Parasit Vectors       Date:  2016-10-10       Impact factor: 3.876

3.  Intake Procedures in Colorado Animal Shelters.

Authors:  Anna Fagre; Francisco Olea-Popelka; Rebecca Ruch-Gallie
Journal:  Animals (Basel)       Date:  2017-05-05       Impact factor: 2.752

Review 4.  Examination of the "susceptibility gap" in the treatment of canine heartworm infection.

Authors:  Dwight D Bowman; Jason Drake
Journal:  Parasit Vectors       Date:  2017-11-09       Impact factor: 3.876

5.  Impact of heat treatment on Dirofilaria immitis antigen detection in shelter dogs.

Authors:  Brian A DiGangi; Carly Dworkin; Jason W Stull; Jeanette O'Quin; Morgan Elser; Antoinette E Marsh; Lesli Groshong; Wendy Wolfson; Brandy Duhon; Katie Broaddus; Elise N Gingrich; Emily Swiniarski; Elizabeth A Berliner
Journal:  Parasit Vectors       Date:  2017-11-09       Impact factor: 3.876

6.  Are vector-borne pathogen co-infections complicating the clinical presentation in dogs?

Authors:  Anna Sara De Tommasi; Domenico Otranto; Filipe Dantas-Torres; Gioia Capelli; Edward B Breitschwerdt; Donato de Caprariis
Journal:  Parasit Vectors       Date:  2013-04-15       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.